Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems (NYSE: VEEV) is scheduled to announce its fourth quarter and full fiscal year results for the period ending January 31, 2023 after market close on March 1, 2023. A conference call and webcast will take place at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. Prepared remarks will be available on the investor relations website at ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET).

Veeva is the global leader in cloud software for the life sciences sector, serving over 1,000 customers, including top pharmaceutical firms and emerging biotech companies.

Veeva Systems (NYSE: VEEV) announced that Adare Pharma Solutions selected the Veeva Vault Quality Suite to streamline quality processes across its operations in the U.S., France, and Italy. This integration will replace legacy systems, enhance collaboration, and improve visibility for customers. The suite includes Veeva Vault QMS for managing quality processes, Vault QualityDocs for document control, and Vault Training for employee qualifications. This partnership aims to support Adare's goals in delivering improved services and transformational medicines.

On January 10, 2023, Veeva Systems (NYSE: VEEV) expressed its support for the FTC's proposed rule to ban non-compete agreements, citing their detrimental effects on innovation and employee rights. Veeva argues that non-competes restrict talent mobility, hinder entrepreneurship, and ultimately harm economic growth and product quality. The company has a history of opposing such agreements and has never required its employees to sign them. CEO Peter Gassner emphasized that banning non-competes is crucial for fostering a competitive and innovative workforce. Veeva aims to eliminate non-competes by 2030 as part of its Public Benefit Corporation mission.

Veeva Systems (NYSE: VEEV) announced that CEO Peter Gassner will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 2:15 p.m. PT in San Francisco. The presentation will be available via live and archived webcast on Veeva's investor relations website.

Veeva is a leader in cloud software for the life sciences industry, serving over 1,000 customers including major pharmaceutical firms and emerging biotech companies.

On December 14, 2022, Veeva Systems announced that Dan Crawford, principal consultant of Veeva Clinical Database, has been elected chair of the CDISC Advisory Council. His role will involve collaborating with top pharma leaders and advising the CDISC board on data standards. Crawford aims to enhance data collection and promote the benefits of CDISC standards, which help expedite clinical trials and regulatory processes. This leadership position reflects Veeva's commitment to innovation in life sciences data management.

Veeva Systems reported total revenues of $552.4 million for Q3 2023, reflecting a 16% year-over-year increase. Subscription services also rose to $441.6 million, marking the same growth rate. Operating income decreased by 9% to $121.4 million, whereas non-GAAP operating income grew 10% to $219.5 million. Net income increased by 2% to $108.5 million and non-GAAP net income surged 16% to $183.2 million. The company also established a 10-year strategic partnership with Merck.

Veeva Systems (NYSE: VEEV) announced that three of the top ten biopharmaceutical companies utilize its Veeva Link Scientific Awareness platform, which provides real-time insights into product awareness and sentiment. This tool enhances the ability of medical teams to refine product strategies and communicate effectively with the scientific community. Veeva Link offers comprehensive analysis from over 300,000 medical congresses and 100 million social media posts, fostering value-driven medical activities. The platform is available in 87 countries and is designed to keep pace with the evolving healthcare landscape.

Veeva Systems (NYSE: VEEV) released its Veeva Pulse Field Trends Report, revealing that U.S. healthcare professional (HCP) access now averages 60%, with key specialties nearing 80%. The report highlights that over 50% of accessible HCPs engage via video, generating 3x promotional response compared to in-person only. Additionally, half of accessible HCPs limit engagements to three companies or less. Companies can leverage this data to optimize field strategies and enhance engagement efficiency, ultimately driving better outcomes in the biopharma industry.

Veeva Systems (NYSE: VEEV) will announce its third quarter financial results on December 1, 2022, following the close of the market. The results will cover the period ending October 31, 2022. A conference call and webcast will take place at 2:00 p.m. PT (5:00 p.m. ET) the same day to discuss these results. Investors can access prepared remarks on Veeva's investor relations website at 1:05 p.m. PT (4:05 p.m. ET). A replay of the webcast will be available afterward.